The Seiden Group announces U.S. Shareholders formation of a group to recover investor funds through a possible Receivership over China-based BioPharm Asia, Inc., (Ticker: BFAR)

NEW YORK, March 21, 2017 /PRNewswire/ -- BioPharm Asia, Inc., (Ticker: "BFAR"), is a Nevada corporation involved in the sale of medical products to drug stores, hospitals, neighborhood clinics, and other medicine retail outlets in the People's Republic of China. BFAR was de-listed from the NASDAQ in June 2013 after it stopped reporting to the Securities & Exchange Commission ("SEC").

Certain shareholders have spoken with Robert W. Seiden, Esq. in New York to represent a group of shareholders to enforce the rights of the U.S. shareholders for acts detrimental to the investors including failure to report to the SEC in order to get a possible return of capital to the investors.

If you are a current shareholder of BFAR and interested in information to consider joining in the case, please email Nathaniel Francis at the email: [email protected] or call 212.626.6709 by April 4, 2017. You can also register on the website www.confidentialglobal.com under "Join Receivership Case".

SOURCE The Seiden Group